- This round brings the company’s total funding to over $150 million since inception
- The largest real-world multi-center study using Viz LVO found a median time-to-notification of 5 minutes and 45 seconds across all of the sites involved when using Viz LVO
Viz.ai today announced that it has raised $71 million in Series C funding, led by Scale Venture Partners and Insight Partners with participation from Greenoaks, Kleiner Perkins, Threshold Ventures, CRV, Innovation Endeavors and Susa Ventures. This round brings the company’s total funding to over $150 million since inception.
Rory O’Driscoll, partner, Scale Venture Partners said, “This expansion addresses the gap in the coordination of care among clinicians and healthcare systems to best facilitate essential and timely patient care. Viz.ai has proven its ability to transform care coordination in stroke by leveraging AI and advanced mobile technology, and we see huge potential for this platform to transform other acute care specialties across healthcare.”
The current system of care is still managed by outdated software, often leading to lack of visibility and delayed patient care which can be costly, particularly in acute emergencies where saving time is essential. The company said that Viz.ai is at the forefront of care coordination transformation with an award winning FDA-cleared product suite running AI-powered real time disease detection, automated alerts and triage, mobile DICOM image viewing, HIPAA-compliant secure messaging, and point of care physician consults that greatly enhances patient care, resulting in exceptional patient outcomes.
The largest real-world multi-center study using Viz LVO found a median time-to-notification of 5 minutes and 45 seconds across all of the sites involved when using Viz LVO. In the study, containing the largest health AI data set to date, Viz LVO achieved 96 per cent sensitivity and 94 per cent specificity in identifying large vessel occlusions in 2,544 consecutive patients from 139 hospitals using scanners from multiple manufacturers, said the company.
Improves patient outcomes and reduces disability
Faster triage with Viz LVO enables the identification and triage of more patients who are eligible for thrombectomy, which not only improves patient outcomes and reduces disability, but also is reimbursed at approximately three times the rate than medically managed stroke.
Chris Mansi, co-founder and CEO of Viz.ai said, “This latest round of funding validates the potential of Viz.ai’s technology, both in and beyond stroke care coordination. The investment will allow us to expedite our effort to bring the power of artificial intelligence and advanced mobile technology to prevent care breakdowns, improve patient outcomes and experience, and improve economics across the entire health system both in the United States and Europe.”
